RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Amyris, a Bay Area bioscience company, will form a JV with Shenzhen’s BGI Genomics to develop human microbiome products for China. Amyris develops fermentation processes that provide health and beauty products as well as synthetic artemisinin for malaria. The JV will combine Amyris’s fermentation capabilities with BGI’s gene sequencing expertise. Ultimately, the JV aims to develop products that promote a healthy microbiome based on natural products, including TCM-based ingredients that are sustainably produced by Amyris’s clean fermentation technology.
Source: China Biotoday
